NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE Drug Patent Profile

Which patents cover Naloxone Hydrochloride And Pentazocine Hydrochloride, and when can generic versions of Naloxone Hydrochloride And Pentazocine Hydrochloride launch?

Naloxone Hydrochloride And Pentazocine Hydrochloride is a drug marketed by Lupin, Sun Pharm Inds Ltd, and Watson Labs. and is included in three NDAs.

The generic ingredient in NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is naloxone hydrochloride; pentazocine hydrochloride. There are twelve drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride; pentazocine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Naloxone Hydrochloride And Pentazocine Hydrochloride

A generic version of NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE was approved as naloxone hydrochloride; pentazocine hydrochloride by WATSON LABS on January 21^st, 1997.

Summary for NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

US Patents:	0
Applicants:	3
NDAs:	3

US Patents and Regulatory Information for NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lupin	NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE	naloxone hydrochloride; pentazocine hydrochloride	TABLET;ORAL	075735-001	Jul 11, 2001	AB	RX	No	No
Sun Pharm Inds Ltd	NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE	naloxone hydrochloride; pentazocine hydrochloride	TABLET;ORAL	075523-001	Mar 17, 2000	AB	RX	No	No
Watson Labs	NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE	naloxone hydrochloride; pentazocine hydrochloride	TABLET;ORAL	074736-001	Jan 21, 1997	AB	RX	No	Yes

Naloxone Hydrochloride and Pentazocine Hydrochloride: Patent Landscape and Investment Fundamentals

Last updated: February 19, 2026

This analysis details the patent landscape, regulatory status, and market fundamentals for naloxone hydrochloride and pentazocine hydrochloride. It provides a foundation for evaluating investment and R&D opportunities related to these compounds, focusing on their current market positions, future potential, and patent protection.

What is the Core Utility of Naloxone Hydrochloride and Pentazocine Hydrochloride?

Naloxone hydrochloride is an opioid antagonist. Its primary function is to rapidly reverse the effects of an opioid overdose. It acts by binding to opioid receptors with higher affinity than most opioids, displacing them and restoring normal respiration. Pentazocine hydrochloride is a synthetic opioid analgesic. It functions as a mixed opioid agonist-antagonist, meaning it can have both opioid-like effects (pain relief) and opioid-blocking effects. Historically, pentazocine has been used for moderate to severe pain management, but its use has been complicated by its mixed agonist-antagonist profile which can lead to withdrawal symptoms in individuals dependent on pure opioid agonists [1].

What is the Current Patent Landscape for Naloxone Hydrochloride and Pentazocine Hydrochloride?

The patent landscape for naloxone hydrochloride and pentazocine hydrochloride is characterized by expired foundational patents for the active pharmaceutical ingredients (APIs) themselves. However, innovation continues in formulations, delivery methods, and combination therapies.

Naloxone Hydrochloride Patents

The original patents covering naloxone hydrochloride as a chemical entity have long expired. Primary market players rely on patents for:

• Novel Formulations:
  • Intranasal Devices: Patents have been granted for specific nasal spray devices designed for rapid and effective naloxone delivery, such as those developed by Narcan (Emergent BioSolutions) [2]. These patents often cover aspects of spray pattern, dose accuracy, and ease of use.
  • Auto-Injector Devices: Patents exist for auto-injector devices, aiming to provide a more user-friendly method for administration, particularly by laypersons. These patents detail mechanisms for needle deployment and drug delivery.
• Combination Therapies:
  • Research and patent filings explore combinations of naloxone with other agents, though these are less prevalent for naloxone as a standalone overdose reversal agent.
• Manufacturing Processes:
  • Patents may cover specific, optimized synthesis routes or purification methods for naloxone hydrochloride, offering cost or efficiency advantages.
• Extended-Release Formulations:
  • While less common for acute overdose reversal, some research has explored sustained-release naloxone for other indications, leading to formulation patents.

Pentazocine Hydrochloride Patents

Similar to naloxone, the basic composition-of-matter patents for pentazocine have expired. Current patent activity focuses on:

• Combination Products:
  • The most significant patent activity for pentazocine hydrochloride revolves around its combination with naloxone hydrochloride. These combination products are designed to provide analgesia while mitigating the potential for abuse or overdose. Examples include:
    • Talwin NX: This product, originally developed by Sanofi-aventis, combined pentazocine hydrochloride with naloxone hydrochloride. Patents for such combinations typically cover the specific ratio of the APIs, the formulation that allows for oral administration of pentazocine while making the naloxone component active upon parenteral abuse (e.g., injection), and the therapeutic benefits of the combination [3].
    • Generics and Reformulations: While the original combination patents may be nearing expiry or have expired, generic manufacturers may seek patents on specific manufacturing processes or new formulations that offer slight improvements or cost advantages.
• Novel Delivery Systems:
  • Research may explore alternative delivery methods for pentazocine, although this is less common than for naloxone, given its primary use as a prescription analgesic.
• New Indications:
  • Patents could be sought for the use of pentazocine or its combinations in treating new pain conditions or other relevant medical needs, provided there is novel therapeutic utility.

What is the Regulatory Status and Market Entry for These Compounds?

The regulatory status and market entry of naloxone hydrochloride and pentazocine hydrochloride differ significantly, reflecting their distinct therapeutic roles and market dynamics.

Naloxone Hydrochloride

• FDA Status: Naloxone hydrochloride is approved by the U.S. Food and Drug Administration (FDA) for the emergency treatment of suspected opioid overdose. It is available by prescription and, in many jurisdictions, over-the-counter (OTC) for public access.
• OTC Transition: In March 2023, the FDA approved the first OTC naloxone nasal spray (Narcan), marking a significant shift in accessibility. This transition from prescription to OTC status aims to expand availability to community settings and reduce barriers to access [4].
• Market Players: Key manufacturers and distributors include Emergent BioSolutions (Narcan®), Vizimpro Pharmaceuticals, and various generic manufacturers.
• Regulatory Considerations: The FDA monitors the safety and efficacy of naloxone products. Post-market surveillance is crucial, especially with increased public access. Manufacturing quality and supply chain integrity are critical regulatory concerns.
• Global Access: Many countries have similar regulatory pathways for naloxone, with efforts underway to increase its availability globally to combat the opioid crisis.

Pentazocine Hydrochloride

• FDA Status: Pentazocine hydrochloride is approved by the FDA as a Schedule IV controlled substance for the management of moderate to severe pain. It is available by prescription only.
• Combination Products (e.g., Pentazocine/Naloxone): Products combining pentazocine with naloxone (e.g., Talwin NX®) were developed to reduce the abuse potential of pentazocine. These are also prescription-only medications.
• Market Players: Historically, Sanofi-aventis was a key player with Talwin® and Talwin NX®. Generic versions of pentazocine and its combinations are available from various pharmaceutical companies.
• Regulatory Considerations: As a Schedule IV controlled substance, pentazocine is subject to strict prescribing, dispensing, and record-keeping requirements under the U.S. Drug Enforcement Administration (DEA). Its abuse potential and diversion are primary regulatory concerns.
• Therapeutic Limitations: Due to its mixed agonist-antagonist profile, pentazocine is generally not a first-line analgesic compared to pure opioid agonists for severe pain. It can also precipitate withdrawal in opioid-dependent individuals.

What are the Key Market Drivers and Future Potential for These Compounds?

The market drivers and future potential for naloxone hydrochloride and pentazocine hydrochloride are shaped by distinct factors: the public health imperative for naloxone and the evolving landscape of pain management for pentazocine.

Naloxone Hydrochloride Market Drivers and Future Potential

• Opioid Crisis Mitigation: The primary driver for naloxone is the ongoing opioid overdose epidemic. Government funding, public health initiatives, and harm reduction strategies globally fuel demand.
• Increased Accessibility: The OTC approval of naloxone nasal spray is a significant market expansion driver. Wider availability in pharmacies, community centers, and public spaces will increase uptake.
• Government Procurement: National and local governments are major purchasers of naloxone for emergency services, public health programs, and distribution to at-risk populations.
• Supply Chain Security: Ensuring a consistent and robust supply chain is critical, as shortages can have severe public health consequences. This drives investment in manufacturing capacity and redundancy.
• Technological Advancements: Further innovation in delivery devices (e.g., more user-friendly injectors, longer-acting formulations for specific use cases) could expand its utility.
• Expanding Indications (Limited): While primarily for overdose reversal, some research might explore its use in managing opioid withdrawal symptoms or preventing relapse, although this is not its core market.
• Competition: The market is competitive, with multiple generic options emerging. Differentiation will likely come from delivery device innovation and supply chain reliability.

Pentazocine Hydrochloride Market Drivers and Future Potential

• Pain Management Needs: Pentazocine serves a niche within the pain management market for moderate to severe pain, particularly when clinicians seek an agent with a potentially lower abuse liability than pure mu-opioid agonists, or when a mixed agonist-antagonist profile is clinically preferred.
• Abuse Deterrence: Combination products like pentazocine/naloxone were developed to deter abuse. Market demand for such formulations persists, though the efficacy of this deterrence is subject to ongoing debate and development of circumvention techniques.
• Controlled Substance Regulations: The market is heavily influenced by the regulatory environment surrounding controlled substances. Stricter controls on pure opioid agonists can indirectly create demand for alternatives like pentazocine, provided it meets clinical needs and can be managed within regulatory frameworks.
• Niche Analgesia: It remains a viable option for specific patient populations and pain types, especially in settings where a less potent or differently acting opioid is desired.
• Generic Market Dynamics: The market for pentazocine and its combinations is largely driven by generic competition, influencing pricing and accessibility.
• Limited Innovation Pipeline: The innovation pipeline for pentazocine itself appears limited. Future growth is more likely to come from optimizing existing formulations or combinations rather than novel pentazocine discoveries.
• Competition from Newer Analgesics: Pentazocine faces competition from a wide array of other analgesics, including non-opioids, other opioids with different pharmacological profiles, and non-pharmacological pain management therapies.

What are the Investment and R&D Considerations?

Evaluating investment and R&D opportunities requires a nuanced understanding of the competitive landscape, regulatory pathways, and market demand for both naloxone hydrochloride and pentazocine hydrochloride.

Naloxone Hydrochloride Investment and R&D Considerations

• Focus on Delivery Systems: Given the expiry of core API patents, R&D investment should prioritize novel or improved drug delivery systems. This includes user-friendly auto-injectors, more efficient nasal sprays, or even emerging technologies like inhaled naloxone. Patents for these delivery mechanisms are crucial for market exclusivity.
• Manufacturing and Supply Chain: Investment in secure, scalable, and cost-effective manufacturing processes is vital. Ensuring a robust supply chain to meet significant public health demand is a key differentiator. Companies with established manufacturing capabilities and reliable distribution networks have a competitive advantage.
• Partnerships and Distribution: Collaborations with public health organizations, government agencies, and emergency service providers are essential for market penetration and demand generation.
• Generic Competition: The market is becoming increasingly commoditized with generic entries. Investment strategies should consider how to differentiate beyond price, perhaps through superior formulation or enhanced patient education support.
• Regulatory Expertise: Navigating the evolving regulatory landscape, particularly the path to OTC status and ongoing pharmacovigilance requirements, demands significant regulatory expertise.
• Market Size: The market for naloxone is substantial and driven by the persistent opioid crisis, offering significant revenue potential.

Pentazocine Hydrochloride Investment and R&D Considerations

• Combination Product Optimization: R&D efforts could focus on optimizing existing pentazocine/naloxone combinations or exploring new ratios and formulations that enhance abuse deterrence while maintaining therapeutic efficacy. Patents in this area would be critical.
• Niche Pain Management Applications: Identifying specific, underserved pain indications where pentazocine's unique pharmacological profile offers an advantage could present R&D opportunities. However, this requires robust clinical trial data and clear differentiation from existing treatments.
• Controlled Substance Management: Investment in understanding and adhering to the stringent regulatory framework for Schedule IV controlled substances is paramount. This includes robust security measures, tracking, and reporting.
• Abuse Deterrent Technologies: While pentazocine/naloxone is a combination for abuse deterrence, further research into advanced abuse deterrent technologies applied to pentazocine could be an area of R&D.
• Generic Market Strategy: For companies focusing on pentazocine, a strategy centered on cost-efficient manufacturing and reliable supply of generic versions of existing pentazocine or pentazocine/naloxone products is the most probable path to market.
• Limited Upside Potential: The overall upside potential for pentazocine may be limited due to its historical use patterns, regulatory controls, and the availability of alternative analgesics. R&D investment must be carefully weighed against these constraints.

Key Takeaways

• Naloxone hydrochloride patents primarily cover novel formulations and delivery systems, as foundational API patents have expired.
• Pentazocine hydrochloride patents are largely focused on combination products with naloxone and specific manufacturing processes.
• Naloxone's OTC approval significantly broadens its market access and demand, driven by the opioid crisis.
• Pentazocine remains a Schedule IV controlled substance analgesic with a niche market, facing regulatory hurdles and competition.
• Investment in naloxone should target delivery innovations and supply chain security.
• Investment in pentazocine is more likely to be in optimizing combination products or generic manufacturing due to limited R&D horizons.

Frequently Asked Questions

1. What is the primary differentiator for naloxone hydrochloride products in the current market? The primary differentiators for naloxone hydrochloride products are the delivery system's ease of use, speed of administration, dose accuracy, and brand reputation, particularly for products like Narcan. With the OTC transition, accessibility and public awareness campaigns also play a crucial role.

2. Can new patents be obtained for naloxone hydrochloride and pentazocine hydrochloride APIs themselves? No, new composition-of-matter patents for naloxone hydrochloride and pentazocine hydrochloride APIs are generally not possible as the original patents have expired. However, patents can be granted for novel polymorphs, enantiomers, or specific salts if they demonstrate unexpected and improved properties, though this is rare for established APIs.

3. How do the DEA scheduling of pentazocine hydrochloride impact its market potential? The Schedule IV classification of pentazocine hydrochloride imposes strict regulations on its manufacturing, distribution, prescription, and dispensing. This limits its widespread use and necessitates robust compliance programs, which can increase operational costs and complexity for manufacturers and prescribers, thereby impacting market potential and accessibility.

4. What is the expected impact of generic competition on the pricing of naloxone hydrochloride? The introduction of generic naloxone hydrochloride products is expected to drive down prices, similar to trends seen with other generic medications. This increased affordability can enhance accessibility, particularly in public health programs and for individual consumers, but it also compresses profit margins for manufacturers.

5. Are there any significant emerging therapeutic areas being explored for pentazocine hydrochloride beyond pain management? While pentazocine's primary role is as an analgesic, historical research has explored its potential in managing opioid withdrawal symptoms or as an adjunct in certain anesthesia protocols. However, significant new therapeutic areas are not widely reported as active R&D pursuits for pentazocine hydrochloride currently, with the focus remaining on its established indications and abuse deterrence.

Citations

[1] National Institute on Drug Abuse. (2020). Opioid Overdose Reversal. Retrieved from https://www.drugabuse.gov/drug-topics/opioids/opioid-overdose-reversal

[2] Emergent BioSolutions Inc. (2024). Narcan® Nasal Spray. Retrieved from https://www.narcan.com/ (Note: Specific patent numbers are typically found within product documentation or patent databases, not directly on the product website.)

[3] Sanofi-aventis. (n.d.). Talwin NX® Prescribing Information. (Archived information related to historical product).

[4] U.S. Food & Drug Administration. (2023, March 29). FDA Approves First Over-the-Counter Naloxone Nasal Spray. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-naloxone-nasal-spray